Progyny Inc Stock News

It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health companies, around two-thirds have lost value this year, while the Nasdaq is up 32%.

SAN DIEGO , Dec. 18, 2024 /PRNewswire/ -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United...

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Investors might be well served by expanding beyond the S&P 500.

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Progyny, Inc. (NASDAQ: PGNY) to determine whether certain Progyny officers and directors violated securities laws and breached fiduciary duties to shareholders. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the Uni...

SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

I recommend downgrading Progyny from buy to hold due to a loss of confidence in its growth outlook and increased uncertainty. PGNY's Q3 2024 results were disappointing, with revenue and margins falling short of expectations, leading to lowered FY24 guidance. Declines in ART cycles and a weaker 2024 sales season raise concerns about underlying demand, despite potential upsides from upselling adj...

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Progyny, Inc. (NASDAQ: PGNY) or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.